About Blackthorn Therapeutics
Blackthorn Therapeutics is a company based in San Francisco (United States) founded in 2014.. Blackthorn Therapeutics has raised $130 million across 4 funding rounds from investors including ARE, Scripps Research and Arch Venture Partners. Blackthorn Therapeutics operates in a competitive market with competitors including Nura Bio, Healx, NEOS Therapeutics, STALICLA and SciNeuro, among others.
- Headquarter San Francisco, United States
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$130 M (USD)
in 4 rounds
-
Latest Funding Round
$76 M (USD), Series B
Jun 13, 2019
-
Investors
ARE
& 10 more
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
15 people
Scientific Team
11 people
Software Development Team
9 people
Senior Team
4 people
Human Resources and Administration
4 people
Product Management Team
4 people
Operations Team
3 people
Legal and Compliance
2 people
Unlock access to complete
Funding Insights of Blackthorn Therapeutics
Blackthorn Therapeutics has successfully raised a total of $130M across 4 strategic funding rounds. The most recent funding activity was a Series B round of $76 million completed in June 2019. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series B — $76.0M
- First Round First Round
- Investors Count 11
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2019 | Amount | Series B - Blackthorn Therapeutics | Valuation | Polaris Partners , Scripps Research | |
| Jan, 2017 | Amount | Series A - Blackthorn Therapeutics | Valuation | Arch Venture Partners , Mercury Fund | |
| Oct, 2016 | Amount | Series A - Blackthorn Therapeutics | Valuation | Arch Venture Partners |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Blackthorn Therapeutics
Blackthorn Therapeutics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include ARE, Scripps Research and Arch Venture Partners. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
US focused venture capital firm
|
Founded Year | Domain | Location | |
|
Private equity & venture capital firm
|
Founded Year | Domain | Location | |
|
-
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Blackthorn Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Blackthorn Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Blackthorn Therapeutics Comparisons
Competitors of Blackthorn Therapeutics
Blackthorn Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Nura Bio, Healx, NEOS Therapeutics, STALICLA and SciNeuro, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Diagnostic solutions and neuroprotective medicines for neurological disorders are provided.
|
|
| domain | founded_year | HQ Location |
AI-powered drug discovery platform for rare diseases is developed.
|
|
| domain | founded_year | HQ Location |
Proprietary platform is utilized for extended-release CNS drug development.
|
|
| domain | founded_year | HQ Location |
Precision medicines for neurodevelopmental disorders are manufactured using DEPI technology.
|
|
| domain | founded_year | HQ Location |
Therapeutic solutions for CNS disorders are developed by SciNeuro.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Blackthorn Therapeutics
Frequently Asked Questions about Blackthorn Therapeutics
When was Blackthorn Therapeutics founded?
Blackthorn Therapeutics was founded in 2014.
Where is Blackthorn Therapeutics located?
Blackthorn Therapeutics is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is Blackthorn Therapeutics a funded company?
Blackthorn Therapeutics is a funded company, having raised a total of $130M across 4 funding rounds to date. The company's 1st funding round was a Series A of $40M, raised on Jun 01, 2014.
What does Blackthorn Therapeutics do?
Blackthorn Therapeutics was founded in 2014 in San Francisco, United States, within the biotechnology sector. A pipeline of treatments for neurodevelopmental disorders is being constructed using the INFORM platform, which connects brain physiology to behavior. The lead program, BTRX-246040, functions as an antagonist of the nociceptin receptor (NOPR), a target associated with various neurobehavioral disorders. Operations focus on advancing these therapeutics for clinical application.
Who are the top competitors of Blackthorn Therapeutics?
Who are Blackthorn Therapeutics's investors?
Blackthorn Therapeutics has 11 investors. Key investors include ARE, Scripps Research, Arch Venture Partners, Polaris Partners, and Premier Partners.